DiaKine Therapeutics, Inc.

With projections that the global diabetes population will grow from 366 million currently to approximately 552 million by 2030, driven by adult-onset type 2 diabetes, biopharma deal-making in diabetes

IN VITRO DIAGNOSTICS Mergers & Acquisitions Alere Inc. eScreen Inc. Point-of-care diagnostics company Alere Inc. has acquired private drugs-of-abuse screening firm eScreen Inc. for $270mm in c

Islet Sciences, which is developing products for insulin-dependent diabetes around its islet cell transplantation technology, is to acquire DiaKine Therapeutics in an all-share deal. DiaKine is develo

Intense interest in the field gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk. Some of the most notable recent fund raisings